Literature DB >> 16868499

Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection.

Joseph B Margolick1, Stephen J Gange, Roger Detels, Maurice R G O'Gorman, Charles R Rinaldo, Shenghan Lai.   

Abstract

BACKGROUND: HIV-1 infection is characterized by an inverted CD4/CD8 T-cell ratio, but the distribution of inversions over time after seroconversion and whether delay of inversion is associated with a favorable prognosis are not known.
METHODS: T-cell counts and clinical outcomes among men in the Multicenter AIDS Cohort Study who had incident HIV-1 infection before December 31, 1995 were analyzed by Kaplan-Meier and Cox proportional hazards methods. Results were also analyzed by time-dependent multivariate methods to adjust for CD4 lymphocyte counts, viral loads, age, race, and polymorphisms in host chemokine receptor genes (CCR5-Delta32 and CCR2-64I).
RESULTS: Among 424 cases whose date of seroconversion was known to within +/-4.5 months, 317, 52, and 55 inverted their CD4/CD8 ratio within less than 1, 1 to 2, and more than 2 years of seroconversion, respectively. Longer time to inversion was significantly associated with longer time to AIDS, even after adjusting for CD4 lymphocyte count and viral load at the first seropositive visit and over the first 3 seropositive visits. Of the 6 seroconverters who had more than 500 CD4 lymphocytes 10 years after seroconversion without receiving highly active antiretroviral therapy, 5 took more than 2 years to invert their CD4/CD8 ratio.
CONCLUSIONS: Time from HIV-1 seroconversion to inversion of the CD4/CD8 ratio independently predicted time to AIDS. Early measurements of the CD4/CD8 ratio until inversion occurs may identify people likely to become long-term nonprogressors or slow progressors, thus facilitating detailed studies of the mechanism of HIV-1 disease progression.

Entities:  

Mesh:

Year:  2006        PMID: 16868499     DOI: 10.1097/01.qai.0000223028.55080.9d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.

Authors:  Hemant Kulkarni; Jason F Okulicz; Greg Grandits; Nancy F Crum-Cianflone; Michael L Landrum; Braden Hale; Glenn Wortmann; Edmund Tramont; Michael Polis; Matthew Dolan; Alan R Lifson; Brian K Agan; Sunil K Ahuja; Vincent C Marconi
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-15       Impact factor: 3.731

2.  The relationship between antibody to R7V and progression of HIV type 1 infection.

Authors:  Joseph B Margolick; Jean M Da Costa Castro; Albert Sanchez; Francois Gemrot; John P Phair; Beth D Jamieson; Charles R Rinaldo; Lisa P Jacobson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-04       Impact factor: 2.205

3.  Individual Differences in CD4/CD8 T-Cell Ratio Trajectories and Associated Risk Profiles Modeled From Acute HIV Infection.

Authors:  Robert Paul; Kyu Cho; Jacob Bolzenius; Carlo Sacdalan; Lishomwa C Ndhlovu; Lydie Trautmann; Shelly Krebs; Somporn Tipsuk; Trevor A Crowell; Duanghathai Suttichom; Donn J Colby; Thomas A Premeaux; Nittaya Phanuphak; Phillip Chan; Eugène Kroon; Sandhya Vasan; Denise Hsu; Adam Carrico; Victor Valcour; Jintanat Ananworanich; Merlin L Robb; Julie A Ake; Somchai Sriplienchan; Serena Spudich
Journal:  Psychosom Med       Date:  2022-07-06       Impact factor: 3.864

Review 4.  Human Immunodeficiency Virus Infection and Host Defense in the Lungs.

Authors:  Tysheena P Charles; Judd E Shellito
Journal:  Semin Respir Crit Care Med       Date:  2016-03-14       Impact factor: 3.119

5.  Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART.

Authors:  Arpi S Terzian; Susan Holman; Niyati Nathwani; Esther Robison; Kathleen Weber; Mary Young; Ruth M Greenblatt; Stephen J Gange
Journal:  J Womens Health (Larchmt)       Date:  2009-12       Impact factor: 2.681

6.  No SEVI-mediated enhancement of rectal HIV-1 transmission of HIV-1 in two humanized mouse cohorts.

Authors:  Erik S Van Dis; Tyler C Moore; Kerry J Lavender; Ronald J Messer; Oliver T Keppler; Jens Verheyen; Ulf Dittmer; Kim J Hasenkrug
Journal:  Virology       Date:  2015-11-21       Impact factor: 3.616

7.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Authors:  Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2010-07-02       Impact factor: 54.908

8.  Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

Authors:  Jean-Michel Molina; Birgit Grund; Fred Gordin; Ian Williams; Mauro Schechter; Marcello Losso; Matthew Law; Ernest Ekong; Noluthando Mwelase; Athanasios Skoutelis; Martin J Wiselka; Linos Vandekerckhove; Thomas Benfield; David Munroe; Jens D Lundgren; James D Neaton
Journal:  Lancet HIV       Date:  2018-01-16       Impact factor: 16.070

9.  CD4:CD8 lymphocyte ratio as a quantitative measure of immunologic health in HIV-1 infection: findings from an African cohort with prospective data.

Authors:  Jianming Tang; Xuelin Li; Matthew A Price; Eduard J Sanders; Omu Anzala; Etienne Karita; Anatoli Kamali; Shabir Lakhi; Susan Allen; Eric Hunter; Richard A Kaslow; Jill Gilmour
Journal:  Front Microbiol       Date:  2015-07-01       Impact factor: 5.640

10.  Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Authors:  Victor Leung; Jennifer Gillis; Janet Raboud; Curtis Cooper; Robert S Hogg; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Sean B Rourke; Chris Tsoukas; Marina B Klein
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.